Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Rucaparib Camsylate

The articles shown below are all about the Rucaparib Camsylate, through these related articles, you can get relevant information, notes in use, or latest trends about the Rucaparib Camsylate. We hope these news will give you the help you need. And if these Rucaparib Camsylate articles can't solve your needs, you can contact us for relevant information.
  • Drug Patent & Exclusivity Expiration Report - Week of March 31 2025

    Drug Patent & Exclusivity Expiration Report - Week of March 31 2025

    2025-03-31

    This week, there are 4 drugs in the patent and exclusivity list. They are: - ASTRAZENECA AB's WAINUA (AUTOINJECTOR), containing active ingredient EPLONTERSEN SODIUM - AZURITY PHARMACEUTICALS INC's HORIZANT, containing active ingredient GABAPENTIN ENACARBIL - BIOXCEL THERAPEUTICS INC's IGALMI, containing active ingredient DEXMEDETOMIDINE HYDROCHLORIDE - PHARMAAND GMBH's RUBRACA, containing active ingredient RUCAPARIB CAMSYLATE Read More